Skip to main content
Premium Trial:

Request an Annual Quote

Akoya, Olink, NanoString, Adaptive Bio, Sema4, Oxford Nanopore Report Preliminary Financial Results

NEW YORK — A number of life science companies on Monday reported preliminary financial results for the fourth quarter and full-year 2021 including Akoya Biosciences, Olink, NanoString Technologies, Adaptive Biotechnologies, Sema4, and Oxford Nanopore Technologies.

Akoya said that it expects fourth quarter revenues to be in the range of $16.0 million to $16.2 million compared to $12.9 million in the year-ago quarter. Analysts, on average, are expecting the Marlborough, Massachusetts-based spatial phenotyping firm to post fourth quarter revenues of $15.4 million. For 2021, Akoya anticipates revenues between $54.8 million and $55.0 million, up from $42.4 million in 2020 and topping the Wall Street consensus estimate of $53.87 million.

Uppsala, Sweden-based proteomics firm Olink said that its fourth quarter 2021 revenues will likely be between $43.2 million and $43.7 million versus $27.2 million in the same period a year earlier. Full-year revenues are projected to be between $94.5 million and $95.0 million, an increase of about 75 percent year over year.

NanoString said that total product and services revenues for the fourth quarter are expected to be $42 million, 18 percent higher than in the year-ago quarter and beating the average analyst estimate of $40.85 million. The firm said that it placed approximately 30 GeoMx Digital Spatial Profiler systems in Q4, increasing its installed base to around 255 systems as of the end of the year. For full-year 2021, Seattle-based NanoString, which sells tools for life science discovery and translational research, anticipates revenues of $144 million, 29 percent higher than 2020 and in line with the consensus Wall Street estimate of $143.7 million.

Adaptive Biotechnologies said that revenues for 2021 are expected to be between $153 million and $154 million versus $98.4 million in 2020. Analysts, on average, are expecting full-year revenues of $153.1 million for the Seattle-based firm.

Sema4 said that its fourth quarter revenues are expected to be between $50 million and $52 million, up from previous guidance of $46.6 million to $49.6 million. Analysts, on average, are expecting fourth quarter revenues of $47.42 million for the Stamford, Connecticut-based genomic and clinical data intelligence platform company. The firm also said that its FY 2021 revenues are expected to exceed its previous guidance of revenues between $201 million and $204 million.

Oxford Nanopore Technologies said that it expects to report FY 2021 total revenue above £126 million ($170.6 million), up around 11 percent year over year from FY 2020 revenues of £113.9 million. It said it expects to report core life science research tools, or LSRT, revenue above £120 million compared to LSRT revenue of £65.5 million in FY 2020, representing annual growth in excess of 83 percent. Its previous guidance was for LSRT revenue of £105 million to £111 million in 2021.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.